Mytrelle at Meeting on the Mesa

Myrtelle Announces Presentation of Encouraging Interim Results from its Phase 1/2 Gene Therapy Trial for Canavan Disease at the 2025 Cell & Gene Meeting on the Mesa

Article Date
October 6, 2025

This article is featured on another website.

Go to article

Related posts

Browse all articles
December 9, 2025

Chime Biologics Announces Strategic Collaboration with TNAX Biopharma, Marking Its First Partnership in Japan

December 9, 2025

Chime Biologics Announces Strategic Collaboration with TNAX Biopharma, Marking Its First Partnership in Japan

February 10, 2026

Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.

February 10, 2026

Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.